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the G-BA website. 104 molecules that had gone through the AMNOG procedure were 
identified and further categorized in order to determine whether they had submit-
ted direct, indirect, or both types of comparisons. The G-BA publications by means 
of the classification score were used to source and quantify the outcome of the deci-
sion. RESULTS: 16 out of the 104 analyzed molecules were found to have submitted 
indirect comparisons. Out of these, the G-BA decisions recognized that 6 molecules 
had mild or significant overall added benefit. All of these 6 molecules presented both 
direct and indirect comparisons. On the other hand, molecules that only submitted 
indirect comparisons were found to have no additional benefit. The most common 
reasons for dismissals of indirect comparisons by IQWiG were the inappropriate 
patient population selection, the choice of inappropriate bridge comparators, and 
that population uniformity was not guaranteed. CONCLUSIONS: These results dem-
onstrate that submission of indirect comparisons alone are unlikely to result in a 
positive added benefit classification by IQWiG and the G-BA. However, if the indirect 
comparison is coupled with a direct comparison, the outcome of the assessment by 
the G-BA is more likely to result in a positive added benefit classification.
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OBJECTIVES: The first step in the route to reimbursement of a new product in 
Germany through the Arzneimittelmarkt-Neuordnungsgesetz (AMNOG) process is an 
assessment of additional benefit, conducted by the Gemeinsamer-Bundesausschuss 
(G-BA), which directly influences pricing negotiations. The G-BA may classify addi-
tional benefit of a new substance as major, considerable, minor or unquantifiable 
benefit or ‘no-benefit’. The analysis was conducted to compare trends of G-BA deci-
sions for new technologies and orphan technologies. Further analysis was conducted 
to identify differences in disease areas for companies planning a European launch 
of a new product. METHODS: A longitudinal database containing all additional ben-
efit decisions made by the G-BA was analyzed. Only one decision was published 
in 2011 so only data from 2012-2014 was explored for robustness. Orphan analysis 
was conducted for products with European Union (EU) orphan designation. Analysis 
by disease area classified products into British National Formulary (BNF) catego-
ries. RESULTS: In 2012-2014, G-BA assessed 99 new technologies and decided 48% of 
products had no additional benefit, 25% had minor additional benefit, 18% had consid-
erable additional benefit and the remainder had unquantifiable additional benefit. No 
technologies have been classified as having major additional benefit. G-BA are unable 
to classify an orphan treatment has having no additional benefit due to the nature of 
orphan designation thus no ‘no-benefit’ decisions of orphan products have been made 
but the G-BA decided that 38% (n= 16) of orphan products had unquantifiable benefit 
and 19% had considerable benefit (n= 3). 34% of decisions were for malignant disease 
and immunosuppression products. 12 of the 19 products found to have considerable 
benefit were for malignant disease and immunosuppression. CONCLUSIONS: A high 
proportion of G-BA decisions have been of no or unquantifiable benefit indicating 
that obtaining a high price in Germany is challenging but more likely for orphan, 
malignant disease and immunosuppression products.
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OBJECTIVES: Information regarding health technology assessment (HTA) require-
ments for orphan drugs in Asia Oceania is limited. The aim of our study was to com-
pare HTA evidentiary requirements for standard and orphan drug appraisals among 
7 Asia Oceania countries/regions. METHODS: A literature and policy review was con-
ducted to identify standard and orphan drug HTA requirements and processes for 
the following countries: Australia, Japan, South Korea and China (further divided into 
regions including Mainland China, Hong Kong, Singapore and Taiwan to capture the 
diverse healthcare markets included in the country). A modified Hutton Framework 
was used to descriptively assess the HTA and reimbursement processes in these 
7 countries/regions. RESULTS: Authorities in Asia Oceania are currently in various 
stages of HTA and reimbursement process development for standard and orphan 
drugs. Of the 7 countries/regions studied, Australia is the only country with distinct 
orphan drug HTA evidentiary requirements and processes compared to standard 
drugs. Cost-effectiveness evidence is required as part of South Korea’s standard HTA 
review, but incremental cost-effectiveness ratio (ICER) thresholds are more lenient 
for orphan drugs. In Hong Kong, orphan drugs are assessed by an independent expert 
review committee, and appraisal criteria weigh heavily on patient characteristics and 
perceived benefit. Several countries/regions include health economics in their stand-
ard HTA review: Taiwan (budget impact, comparative effectiveness) and Singapore 
(cost-effectiveness); both countries/regions have similar evidentiary requirements 
for orphan and standard drugs. Japan is in early stages of developing HTA procedures 
and requires minimal economic evidence in standard and orphan drug assessment. 
Mainland China does not have a centralized HTA process for standard and orphan 
drugs. CONCLUSIONS: Most Asia Oceania countries/regions are still developing their 
HTA policies. Due to lack of distinct orphan drug HTA procedures in Taiwan, Singapore, 
Mainland China, and Japan, obtaining reimbursement for drugs may require addi-
tional efficacy or health economic analyses.
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decreasing from 65% in 2005 (n= 17) to 47% in 2013 (n= 15) but then drastically improv-
ing to 82% in 2014 (n= 22). The BNF category with the highest recommendation rate 
was infections (88%, n= 102); conversely, the gastro-intestinal system category had 
the lowest recommendation rate (55%, n= 42). CONCLUSIONS: Results suggest that 
HTA trends in Scotland were reformed in 2014 by changes in the SMC process, which 
included the aim of improving patient access to cancer medications. Recent changes 
implemented by SMC as a result of the Routledge review may provide hope to compa-
nies preparing to navigate the SMC process with oncology, immunology or infection 
products, but companies with products in other areas should explore all considera-
tions through further analyses to maximise market access opportunities in Scotland.
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OBJECTIVES: The Scottish Medicines Consortium (SMC) recommend the use of 
cost-minimization analysis for: therapeutically equivalent treatments established 
through non-inferiority studies; indirect comparisons showing statistically insig-
nificant difference; or where cost-utility analysis shows extremely small quality-
adjusted life year differences between treatments. When a new medicine has 
identical benefits to the comparator, the SMC chooses the cheaper option. In 2014, 
the Office for Health Economics found that whilst the SMC does not specify a type 
of economic analysis for biosimilars, cost-minimization analysis had been used for 
all approved submissions. We examine longitudinal trends and probabilities of rec-
ommendation for any companies using cost-minimization analysis. METHODS: All 
analyses were based on a validated, longitudinal database of all recommendations 
from 2002 to 2014. SMC recommendations following full submission, resubmis-
sions or abbreviated submissions were reviewed to provide some insight into the 
considerations that companies should include in their strategic plans. RESULTS: 
Since 2010, there has been an increasing trend for the use of cost-minimization 
analysis with 35% of full submissions in 2014 using cost-minimization, as well as 
25% of resubmissions. Of the 68 cost-minimization submissions, 24 have received 
positive recommendation, 35 restricted and 9 not recommended. Cost minimiza-
tion has been used in the greatest proportion of respiratory submissions (47% of 
submissions, n= 8, 88% recommended) and infections (43% of submissions, n= 6, 
100% recommended) but most cost-minimization submissions are for endocrine 
treatments (30% of submissions, n= 11, 91% recommended). The recommendation 
rates per BNF category vary greatly with no distinct category having greater suc-
cess. CONCLUSIONS: A manufacturer is most likely to gain a restricted recom-
mendation following submission of cost-minimization analysis. There is no distinct 
BNF category that has a greater chance of success using cost-minimization analysis. 
To recommend with cost-minimization analysis, the SMC must be certain that the 
comparators are appropriate and effectiveness is comparable.
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OBJECTIVES: Considering official introduction of pharmacoeconomic require-
ments in Japanese healthcare policy in 2016, we aimed to assess whether the qual-
ity of pharmacoeconomic studies in Japan has been improved over time, and what 
aspects are in need for further improvement. METHODS: The literature review 
approach was taken for English-language articles via PubMed (Japan AND “Cost-
Benefit Analysis”[Mesh]) and Embase (Japan AND cost effectiveness), and also for 
Japanese-language via Web service of Japan Medical Abstracts Society (“hiyo-tai-
koka” in Japanese, which means “cost-effectiveness”), excluding review articles, 
commentaries, methodological studies, and letters. After eligibility screening, we 
eventually obtained 174 articles as subjects, which were summarized and assessed 
regarding the quality of reporting on whether to state the five factors explicitly: 1) 
study perspective, 2) reason of discount rate, 3) year of currency, 4) time horizon, and 
5) comparator. For each of those factors, we examined a proportion of satisfaction, 
i.e., a percentage of the articles having clearly described the target factor among all 
the articles. In addition, the proportions were compared by the other nominal fac-
tors such as founding source, intervention type, and QALY employment. RESULTS: 
The number of publications has been increasing over time. Over 60 % of studies, 
however, did not clearly disclose their funding sources. The studies without any 
funding disclosure revealed less satisfaction in each of the five factors. Those with 
disclosure of industry-funding had higher satisfaction rates compared to the studies 
with public-funding disclosure or without funding disclosure. Although the stud-
ies which employed QALY as the outcome measure earned high satisfaction of the 
five factors, no totally positive improvement was observed over time in terms of 
satisfaction for any of the five factors. CONCLUSIONS: The quality of reporting the 
Japanese health economic evaluations was not yet satisfactory, and remains further 
challenges for quality improvement to comply with the international standards.
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OBJECTIVES: The AMNOG assessment procedure requires that manufacturers sub-
mit indirect comparisons for the assessment of molecules in the absence of direct 
comparisons versus the G-BA appropriate comparator. The purpose of this study 
was to understand the role that indirect comparisons have in IQWiG’s assessment 
of added benefit and consequently also on the G-BA decision outcome. METHODS: 
The IQWiG assessments and G-BA evaluations through the AMNOG process from 
initial implementation to the end of 2014 were analyzed based on publications from 
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OBJECTIVES: The objective of this study was to analyze recent HTA decisions in 
Taiwan and Korea, and determine the influence on the outcome by HTA decision 
in Australia and the UK. METHODS: This study examined 30 high-cost drugs that 
were FDA and EMA approved from 2011-2014. Two-thirds of the sample were oncol-
ogy drugs, while the remaining one-third included drugs treating multiple sclerosis, 
chronic hepatitis C and type 2 diabetes. The HTA decisions of these products in Taiwan 
and Korea were analyzed as well as in their frequently referenced countries, Australia 
and the UK. RESULTS: Of the 30 products studied, 24 products were assessed by PBAC 
in Australia and 15 products were evaluated by NICE in the UK, while only 9 products 
received HIRA assessments in Korea and 5 products were assessed by the CDE in 
Taiwan. The difference in favorable HTA outcomes among these countries was even 
greater. Only 2 products received positive HTA decisions in Taiwan and Korea, while 
8 and 11 products were recommended in Australia and the UK respectively. Among 
the 8 products evaluated by HIRA, and previously assessed by PBAC and NICE, 6 prod-
ucts received the same decisions as PBAC and / or NICE. The correlation coefficient 
between HIRA and PBAC decisions was 0.75. Similarly, all 5 products assessed by the 
CDE received similar evaluations to those of PBAC and / or NICE, and the correla-
tion coefficient between CDE and PBAC decisions was 1. CONCLUSIONS: Access to 
medicine in Asia, even in wealthy countries like Taiwan and Korea, still largely lags 
behind Western countries like Australia and the UK. In Taiwan and Korea, where phar-
macoeconomic assessment is a key component in the HTA evaluation, HTA decisions 
may be greatly influenced by the HTA outcomes in countries like Australia and the 
UK where pharmacoeconomic evaluation is well-established.
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OBJECTIVES: Between January 2007 and September 2014 NICE report that they 
have made 65 health technology assessment decisions categorized by them as a 
“recommended in line with clinical practice” (RiLwCP). This categorization is not 
explained and implications for patient access are not clear. Using a previously 
developed method, we calculate the degree of recommended access for these deci-
sions. In order to facilitate understanding we also develop a taxonomy for the fac-
tors underlying these decisions. METHODS: In a previously published paper we 
developed a measure, M, to summarize access associated with NICE technology 
optimized appraisal decisions. This was defined as M= (p/P)X100, where M is a meas-
ure of the level of patient access (0 equals no access, 100 full access), P is the set of 
patients considered in the guidance as potential candidates for treatment (given 
the scope of appraisal and license), and p is the number of patients for whom NICE 
did recommend. We applied measure M to the 65 RiLwCP decisions made between 
January 2007 and September 2014. Then assessing the guidance documents pub-
lished for these decisions we identified six themes driving specific recommenda-
tions: reference to a previous NICE TA, existence of a relevant clinical guideline, the 
technology fits within an established pathway of care, clinical opinion, clinical/cost-
effectiveness matching, non-pharmaceutical. RESULTS: for 65 decisions between 
January 2007 and september 2014 m was 66. Among the factors underlying RiLwCP 
decisions the most common were instances where the committee matched cost 
and clinical effectiveness evidence, doing so in 37% of cases. CONCLUSIONS: The 
results for this period suggest that many RiLwCP decisions have the same charac-
teristics as those classified as “optimized” by NICE; notably that use is restricted to 
a subgroup of patients relative to license and this is done for clinical and/or cost 
effectiveness considerations.
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OBJECTIVES: G-BA and NICE are two influential HTA agencies: both are large mar-
kets for pharmaceuticals, many countries look to Germany for reference pricing, 
and NICE decisions are referenced in other agencies’ assessments. Both agencies 
review clinical efficacy versus a comparator. NICE also evaluates the cost-effec-
tiveness. The output of a G-BA review is the “additional benefit” score, while for 
NICE it is an incremental cost-effectiveness ratio (ICER). Because both outcomes 
are dependent on the clinical evaluation, we hypothesize that G-BA’s additional 
benefit score and NICE’s ICER is inversely related. The relationship between NICE 
and G-BA is useful for manufacturers trying to predict reimbursement in these 
markets and globally. Our objective is to examine how G-BA’s additional benefit 
decision correlates to NICE’s reimbursement decision and to the most probable 
incremental cost-effectiveness ratio (ICER). METHODS: G-BA assessments were 
matched to NICE final guidances. G-BA’s additional benefit was extracted and 
compared to the NICE reimbursement decision (categorized as positive or nega-
tive) and the ERG’s most probable ICER. In instances where there were multiple 
ICERs reported (e.g. due to different comparators), the lowest ICER was used. If 
a drug “dominated” the comparator, an ICER of 0 was used. RESULTS: 138 G-BA 
additional benefit decisions were compared to 34 NICE final guidelines. 56% the 
G-BA assessments resulted in a “no additional benefit” score and the second most 
prevalent score was “minor additional benefit” (20%). 82% of NICE decisions were 
positive. There was no difference in the distribution of additional benefit scores by 
NICE decision. There was not a strong correlation between additional benefit and 
the ICER (r= 0.09). CONCLUSIONS: There does not appear to be a trend for G-BA 
to issue better additional benefits to drugs with a positive NICE decision and for 
drugs with a better additional benefit decision to have a lower ICER.
OBJECTIVES: The analysis was conducted to compare trends in recommenda-
tions for orphan and non-orphan products reviewed by the Scottish Medicines 
Consortium (SMC), the National Institute of Health and Care Excellence (NICE) 
and the Gemeinsamer Bundesausschuss (G-BA), and identify disease areas that 
may be particularly challenging for manufacturers planning European product 
launches. METHODS: The following were categorized as ‘recommended’: NICE 
and SMC positive and restricted recommendations, G-BA major, minor and con-
siderable additional benefit decisions; and ‘unable to recommended’: NICE nega-
tive recommendations, SMC negative recommendations and non-submissions, 
G-BA no-benefit or unquantifiable benefit. Analysis of products by disease area 
was conducted by classification into British National Formulary (BNF) catego-
ries. RESULTS: SMC, NICE and G-BA have published 1160, 147 and 100 recom-
mendations since their formation. Positive recommendations from NICE/SMC 
have increased in 2012-2014 (58% to 74%) but decreased from G-BA (50% to 43%). 
Treatments for malignant disease and immunosuppression formed the largest 
category of submissions (SMC 244, NICE 70, G-BA 34) with higher recommenda-
tion rates in Germany (65%) than the UK (50%). Significant differences in recom-
mendations between the UK and Germany were found in endocrine treatments 
(73% vs. 24%, p= 0.00003) and eye treatments (74% vs. 20%, p= 0.012). In 2011-2014, 
NICE and G-BA only evaluated 9 and 16 orphan products, respectively. Overall, 
NICE has recommended more orphan products (67%) than G-BA (63%) or SMC 
(49%). NICE and SMC recommendations for orphan products have increased in 
2014 compared to previous years. CONCLUSIONS: This analysis illustrates that 
the UK market may be easier to access than the German market but the scale of 
the challenge depends on the BNF category of the treatment. The next stage of 
analysis will consider trend analysis when accounting for SMC resubmissions and 
the re-review of NICE technology appraisals and multiple technology appraisals.
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OBJECTIVES: The statutory health insurance in Germany comprises 90% of the 
German population covering nearly all healthcare services with only little co-
payments. German health insurance claims data therefore constitute an important 
basis for real world evidence (RWE) on epidemiology and cost information. Aim 
of this study was to investigate to which extent RWE was used for estimation of 
prevalence and incidence in German AMNOG assessments since introduction 4 
years ago and also its impact on price discounts. METHODS: German AMNOG 
assessments submitted until December 2014 were evaluated. They were screened 
for use of RWE in assessing prevalence and incidence and also target populations. 
After description and discussion of methods and data sources used, statistics 
were applied to explore a potential influence of use and quality of RWE data on 
price discounts. RESULTS: In total, 108 AMNOG dossiers were included. Real world 
evidence was used in 42.6% of these dossiers to assess prevalence and incidence 
as well as target populations. German claims data were employed in 8 dossiers 
(7.4%), registry data in 7 dossiers (6.5%), other data sources like Delphi panels 
in 37 dossiers (34.3%). The impact of quality of RWE evidence on negotiated dis-
counts is inconclusive with limited data available. German claims data comprise 
comprehensive information such as demographics, outpatient and inpatient care, 
prescriptions, devices and aids, incapacity to work and sick leave payments. The 
routine documentation of diagnoses, procedures and prescriptions as well as the 
ability to evaluate patient histories are particularly useful for prevalence and 
incidence analyses, especially regarding the target population and cost estima-
tions which are of paramount importance in price negotiations following the 
AMNOG assessment. CONCLUSIONS: German claims data constitute a valuable 
and valid data source for assessing epidemiologic evidence in German AMNOG 
assessments. Indication specific claims data analyses are a meaningful comple-
ment to literature research.
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OBJECTIVES: Meta-analysis (MA) of time to event survival data are most commonly 
performed using the individual summary statistic hazard ratio from each study, as 
an appropriate measure of effect. Currently there is no clear guidance regarding 
alternative novel methodologies of evidence synthesis using survival data which 
violates the proportional hazards (PH) assumption. The aim of this study was to 
assess: (i) the guidance from HTA bodies in relation to the MA of time to event 
survival data; (ii) technology assessments (TAs) submitted to NICE to determine 
the level of supporting information relating to the PH assumption accompany-
ing MAs of time to event data in manufacturer submissions, and the response of 
reimbursement authorities. METHODS: HTA authorities guidelines (NICE, PBAC, 
IQWIG, CADTH, NCPE) were searched to identify information relating to the MA 
of time to event data. The NICE website was interrogated to identify TAs and the 
associated ERG/FAD reports in the oncology setting (published 2011–2014) report-
ing MAs of time to event data. RESULTS: Of the guidelines searched, the NICE, 
PBAQ and IQWIG guidelines for evidence synthesis refer to the consideration of the 
proportional hazards assumption when performing MA of time to event survival 
data. Of the most recent 60 NICE TAs, seven included the analysis of time to event 
data, however none commented upon the PH assumption. CONCLUSIONS: The 
impact of failing to consider the validity of the PH assumption for MA of time to 
event data in manufacturer submissions is unclear. The failure of trialists and 
statisticians to investigate the validity of the PH assumption for time to event 
data used in evidence synthesis may result in clinical decisions based on inap-
propriate methods.
